Explore
Validate
LearnPAB3041
antibody from Abnova Corporation
Targeting: FGFR2
BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB3041 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB3041, RRID:AB_1574870
- Product name
- FGFR2 polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of FGFR2.
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.
Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line.
Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM
Cancer research 2003 Oct 1;63(19):6237-43
Cancer research 2003 Oct 1;63(19):6237-43
P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.
Fomenkov A, Huang YP, Topaloglu O, Brechman A, Osada M, Fomenkova T, Yuriditsky E, Trink B, Sidransky D, Ratovitski E
The Journal of biological chemistry 2003 Jun 27;278(26):23906-14
The Journal of biological chemistry 2003 Jun 27;278(26):23906-14
Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line.
Goriely A, McVean GA, Röjmyr M, Ingemarsson B, Wilkie AO
Science (New York, N.Y.) 2003 Aug 1;301(5633):643-6
Science (New York, N.Y.) 2003 Aug 1;301(5633):643-6
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- The FGFR2 polyclonal antibody (Cat # PAB3041) is used in Western blot to detect FGFR2 in Jurkat cell lysate.
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot analysis of FGFR2 polyclonal antibody (Cat # PAB3041) in 293 cell line lysates transiently transfected with the FGFR2 gene (2 ug/lane). hFGFR2-R22 (arrow) was detected using the purified polyclonal antibody.
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- FGFR2/isolectinB4 (A) and FGFR1/isolectinB4 (B) staining of apparent mesenchymal cells and the subpopulation of endothelial cells. Virtually all other dispersed apparent mesenchymal cells express FGFR1 and FGFR2 (merged image in C). F: FGFR2 (D) and FGFR1 (E) staining in clustered cells of epithelial origin (inferred by morphology here) demonstrating that epithelial cells express both FGFR1 and FGFR2 (merged image with DAPI staining in F).
- Validation comment
- Immunofluorescence
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Formalin-fixed and paraffin-embedded human cancer tissue reacted with FGFR2 polyclonal antibody (Cat # PAB3041) , which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma.
- Validation comment
- Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
